Igenomix Acquires Access Genomics Canada from Persistence Capital Partners
December 14, 2020
Igenomix, a Spanish reproductive-genetics company, acquired Toronto-based laboratory Access Genomics (Access Genomics Canada) from Persistence Capital Partners on December 14, 2020. The acquisition expands Igenomix’s presence in North America and strengthens its ability to serve fertility clinics in the Toronto area.
- Buyers
- Igenomix
- Targets
- Access Genomics (Access Genomics Canada)
- Sellers
- Persistence Capital Partners
- Industry
- Biotechnology
- Location
- Ontario, Canada
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
-
EQT Acquires Igenomix from Charme Capital; Management and Charme Reinvest
June 18, 2019
Biotechnology
EQT VIII (EQT Partners) has agreed to acquire a majority stake in Igenomix, a Valencia-headquartered leader in reproductive genetic services, from Charme Capital, management and other minority owners. Charme Capital and the Igenomix management team will reinvest significant minority stakes, and EQT will support the company's continued international expansion and R&D-led growth.
-
Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business
July 15, 2019
Healthcare Services
Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.
-
Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)
October 4, 2022
Biotechnology
Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.
-
Dotmatics Acquires SoftGenetics to Expand Genetic Analysis Capabilities
June 12, 2023
Software
Dotmatics has acquired SoftGenetics, a bioinformatics software company that provides genetic analysis tools for research, clinical, and forensic applications. The acquisition expands Dotmatics' R&D scientific software portfolio by adding SoftGenetics' suite of sequencing and genotyping products while allowing SoftGenetics to operate as a standalone business within Dotmatics.
-
Vitrolife Acquires Igenomix from EQT and Charme for EUR 1.25 billion
July 8, 2021
Healthcare Services
Vitrolife AB has agreed to acquire Igenomix from EQT Private Equity and Charme Capital Partners for an enterprise value of EUR 1.25 billion. The deal combines Vitrolife's IVF product business with Igenomix's reproductive genetic testing capabilities to create a global leader in reproductive health; sellers will retain minority stakes in Vitrolife and the transaction will be funded with cash and newly issued shares.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.